Review



anti-sars-cov-2-quantivac-elisa, s1 quant igg  (EUROIMMUN)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    EUROIMMUN anti-sars-cov-2-quantivac-elisa, s1 quant igg
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Anti Sars Cov 2 Quantivac Elisa, S1 Quant Igg, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/anti+sars+cov+2+elisa++igg+/pmc09578597-52-6-25
    Average 90 stars, based on 1 article reviews
    anti-sars-cov-2-quantivac-elisa, s1 quant igg - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2"

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0263861

    ( A ) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Figure Legend Snippet: ( A ) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.

    Techniques Used: Neutralization, Inhibition, Binding Assay, Infection

    Ratios between SARS-CoV-2 neutralizing antibody titers and ( A, C, D ) RBD IgGAM, S1 IgA, IWV in sample/calibrator ratios and ( B ) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2–3 mild and 4–5 severe). * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.
    Figure Legend Snippet: Ratios between SARS-CoV-2 neutralizing antibody titers and ( A, C, D ) RBD IgGAM, S1 IgA, IWV in sample/calibrator ratios and ( B ) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2–3 mild and 4–5 severe). * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Techniques Used:

    (A) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with inhibitor titer 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine sera calculated as ratio of value on timepoint P1 to timepoint P3.
    Figure Legend Snippet: (A) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with inhibitor titer 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine sera calculated as ratio of value on timepoint P1 to timepoint P3.

    Techniques Used: Neutralization, Binding Assay

    The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Proportion of individuals with remaining nAbs in percent. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.
    Figure Legend Snippet: The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Proportion of individuals with remaining nAbs in percent. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Techniques Used: Neutralization, Inhibition

    SARS-CoV-2 nAb titers on the wildtype strain wt-BavPat1 and the VOC strains Delta, Beta and Omicron after third vaccination (Boost) (A) compared to P1 two weeks after second vaccination and (B) compared to P3 8 months after first and third vaccination (Boost). Only individuals that had provided samples at both time points were compared. The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Mean neutralizing titer reductions are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.
    Figure Legend Snippet: SARS-CoV-2 nAb titers on the wildtype strain wt-BavPat1 and the VOC strains Delta, Beta and Omicron after third vaccination (Boost) (A) compared to P1 two weeks after second vaccination and (B) compared to P3 8 months after first and third vaccination (Boost). Only individuals that had provided samples at both time points were compared. The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Mean neutralizing titer reductions are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Techniques Used: Neutralization, Inhibition

    Related Articles

    Binding Assay:

    Article Title: Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications
    Article Snippet: Blinded replicate sample Sample no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 EUROIMMUN IgG S1 Qual 29.8 6 90.2 7.2 6.9 2.1 15.8 14.3 9.1 6.7 8.1 8.5 7.6 7.7 9.4 EUROIMMUN IgG S1 Quant 39.7 8.8 140.7 15.5 12.4 6.3 24.3 26.5 20.9 7.9 *** *** *** *** *** EUROIMMUN IgG N SemiQuant 33.1 12.4 24.8 13.6 13.6 17.1 17.5 26.2 33.6 15.2 6.2 23.4 15.8 14.6 22.6 EUROIMMUN IgA S1 SemiQuant 19.3 23.6 53.6 12.6 9.1 6.5 26.9 18 51.8 8.4 8.5 16.5 8.8 * 23.1 Roche Elecsys Total Ig N Qual 84 4.7 2.8 4.1 *** *** 4.4 2.6 4.8 10.8 3.5 7.4 7 3.5 4.3 Roche Elecsys Total Ig S Quant 60.6 4.4 14.4 4.7 7.9 *** 5.6 *** *** *** *** *** *** *** *** DiaSorin Trimeric IgG S1/S2 Quant 21.1 37.9 18.3 15.4 21.6 18.9 37.2 33.6 15.7 22.5 11.1 20.9 42.2 11 24.2 Siemens ADVIA Total Ig S1/RBD Qual 12.3 25.8 21.4 *** *** *** *** *** *** *** *** *** *** *** *** Siemens ADVIA IgG S1/RBD Quant 24.8 39.8 20.8 17.1 21.5 20.6 39.7 35.4 8.9 17.4 19.4 23 47.9 7.3 29.9 Abbott IgG N Qual (Alinity) 70.7 17.7 6.6 9.1 6.4 8.9 19.7 31.1 35.8 7.5 8.9 13.1 9.4 12.1 13 Abbott IgG S1 Quant (Alinity) 62.5 19.1 28.4 19 13 19.7 40.1 54.7 15.4 20.4 22.1 37.2 16 14.6 51.1 Abbott IgG N Qual (ARCHITECT) 66.5 15.5 6.1 11.6 9.5 5.4 18.9 33.3 7.7 8.3 *** 14.6 4.4 3.5 2.3 Abbott IgG S1 Quant (ARCHITECT) 55.4 21.8 22.6 15.7 20.2 12.2 43 53.4 12.7 19.4 22.4 28.1 14.2 16.4 50.6 Bio-Rad BioPlex MPX IgG RBD 21.4 29.3 19 7.2 11.8 6.5 18.6 16.7 15.9 15.9 5.6 17.8 22.2 10.4 18.4 Bio-Rad BioPlex MPX IgG S1 24 34.9 20.9 6.3 10.4 7.3 18.4 20.7 15.9 13.3 5.4 21.8 25.6 10.8 21 Bio-Rad BioPlex MPX IgG S2 21.1 22.3 ** 5 12.9 11.9 19 14.8 10.8 13.3 11.7 20.5 14.2 10 19 Bio-Rad BioPlex MPX IgG N 25.7 30.9 22 5.1 12.7 8.6 20.1 21.3 8.1 13 6.2 20.1 16.1 15 23.8 Bio-Rad Platelia Total Ig N SemiQuant 24.4 11.3 6.6 *** *** *** *** *** *** *** *** *** *** *** *** Beckman Coulter Access IgG S1/RBD 9.5 23.3 11.3 19.2 25 17.2 16.9 44.7 12.9 12.6 16.7 17 21.5 9.8 8.4 Diazyme DZ-Lite IgG N/S 18.6 22.4 22.6 22.3 24.3 30.8 27.1 76.5 8.8 17 25.2 33.3 14.4 37.7 14.1 Wantai Total Ig S/RBD 23.5 8.2 24.7 13.2 13 11.7 11.8 10.8 14.2 77.6 39.3 9.3 4.8 7.6 9.5 Ortho VITROS Total Ig S 11 11.3 7.3 7.3 4.4 7.2 14.6 3.3 13.4 6.4 16.1 6.4 4.6 7.4 7.1 S, spike protein; RBD, receptor binding domain; N, nucleocapsid; Ag, antigen; Ab, antibody; Ig, immunoglobulin. .. Blinded replicate sample Sample no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 EUROIMMUN IgG S1 Qual 29.8 6 90.2 7.2 6.9 2.1 15.8 14.3 9.1 6.7 8.1 8.5 7.6 7.7 9.4 EUROIMMUN IgG S1 Quant 39.7 8.8 140.7 15.5 12.4 6.3 24.3 26.5 20.9 7.9 *** *** *** *** *** EUROIMMUN IgG N SemiQuant 33.1 12.4 24.8 13.6 13.6 17.1 17.5 26.2 33.6 15.2 6.2 23.4 15.8 14.6 22.6 EUROIMMUN IgA S1 SemiQuant 19.3 23.6 53.6 12.6 9.1 6.5 26.9 18 51.8 8.4 8.5 16.5 8.8 * 23.1 Roche Elecsys Total Ig N Qual 84 4.7 2.8 4.1 *** *** 4.4 2.6 4.8 10.8 3.5 7.4 7 3.5 4.3 Roche Elecsys Total Ig S Quant 60.6 4.4 14.4 4.7 7.9 *** 5.6 *** *** *** *** *** *** *** *** DiaSorin Trimeric IgG S1/S2 Quant 21.1 37.9 18.3 15.4 21.6 18.9 37.2 33.6 15.7 22.5 11.1 20.9 42.2 11 24.2 Siemens ADVIA Total Ig S1/RBD Qual 12.3 25.8 21.4 *** *** *** *** *** *** *** *** *** *** *** *** Siemens ADVIA IgG S1/RBD Quant 24.8 39.8 20.8 17.1 21.5 20.6 39.7 35.4 8.9 17.4 19.4 23 47.9 7.3 29.9 Abbott IgG N Qual (Alinity) 70.7 17.7 6.6 9.1 6.4 8.9 19.7 31.1 35.8 7.5 8.9 13.1 9.4 12.1 13 Abbott IgG S1 Quant (Alinity) 62.5 19.1 28.4 19 13 19.7 40.1 54.7 15.4 20.4 22.1 37.2 16 14.6 51.1 Abbott IgG N Qual (ARCHITECT) 66.5 15.5 6.1 11.6 9.5 5.4 18.9 33.3 7.7 8.3 *** 14.6 4.4 3.5 2.3 Abbott IgG S1 Quant (ARCHITECT) 55.4 21.8 22.6 15.7 20.2 12.2 43 53.4 12.7 19.4 22.4 28.1 14.2 16.4 50.6 Bio-Rad BioPlex MPX IgG RBD 21.4 29.3 19 7.2 11.8 6.5 18.6 16.7 15.9 15.9 5.6 17.8 22.2 10.4 18.4 Bio-Rad BioPlex MPX IgG S1 24 34.9 20.9 6.3 10.4 7.3 18.4 20.7 15.9 13.3 5.4 21.8 25.6 10.8 21 Bio-Rad BioPlex MPX IgG S2 21.1 22.3 ** 5 12.9 11.9 19 14.8 10.8 13.3 11.7 20.5 14.2 10 19 Bio-Rad BioPlex MPX IgG N 25.7 30.9 22 5.1 12.7 8.6 20.1 21.3 8.1 13 6.2 20.1 16.1 15 23.8 Bio-Rad Platelia Total Ig N SemiQuant 24.4 11.3 6.6 *** *** *** *** *** *** *** *** *** *** *** *** Beckman Coulter Access IgG S1/RBD 9.5 23.3 11.3 19.2 25 17.2 16.9 44.7 12.9 12.6 16.7 17 21.5 9.8 8.4 Diazyme DZ-Lite IgG N/S 18.6 22.4 22.6 22.3 24.3 30.8 27.1 76.5 8.8 17 25.2 33.3 14.4 37.7 14.1 Wantai Total Ig S/RBD 23.5 8.2 24.7 13.2 13 11.7 11.8 10.8 14.2 77.6 39.3 9.3 4.8 7.6 9.5 Ortho VITROS Total Ig S 11 11.3 7.3 7.3 4.4 7.2 14.6 3.3 13.4 6.4 16.1 6.4 4.6 7.4 7.1 S, spike protein; RBD, receptor binding domain; N, nucleocapsid; Ag, antigen; Ab, antibody; Ig, immunoglobulin. ..



    Similar Products

    vitros sars-cov-2 s1 quant igg antibody reagent  (Quidel)
    90
    Quidel vitros sars-cov-2 s1 quant igg antibody reagent
    Vitros Sars Cov 2 S1 Quant Igg Antibody Reagent, supplied by Quidel, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/lyra+sars+cov+2+assay/pmc10411726-124-10-18
    Average 90 stars, based on 1 article reviews
    vitros sars-cov-2 s1 quant igg antibody reagent - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    anti-sars-cov-2-quantivac-elisa, s1 quant igg  (EUROIMMUN)
    90
    EUROIMMUN anti-sars-cov-2-quantivac-elisa, s1 quant igg
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Anti Sars Cov 2 Quantivac Elisa, S1 Quant Igg, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/anti+sars+cov+2+elisa++igg+/pmc09578597-52-6-25
    Average 90 stars, based on 1 article reviews
    anti-sars-cov-2-quantivac-elisa, s1 quant igg - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    anti-s1 igg ii quant  (Abbott Laboratories)
    90
    Abbott Laboratories anti-s1 igg ii quant
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Anti S1 Igg Ii Quant, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/anti+s1+igg+ii+quant/pm35809422-381-207-212
    Average 90 stars, based on 1 article reviews
    anti-s1 igg ii quant - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    anti-s1: sars-cov-2 igg ii quant  (Abbott Laboratories)
    90
    Abbott Laboratories anti-s1: sars-cov-2 igg ii quant
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Anti S1: Sars Cov 2 Igg Ii Quant, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/sars+cov+2+igg+assay/pmc09251959-176-17-22
    Average 90 stars, based on 1 article reviews
    anti-s1: sars-cov-2 igg ii quant - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    igg s1 quant igg spike  (EUROIMMUN)
    90
    EUROIMMUN igg s1 quant igg spike
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Igg S1 Quant Igg Spike, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/s1+igg+elisa/pmc08888213__21___1885___Techapp___s1-19-161-160
    Average 90 stars, based on 1 article reviews
    igg s1 quant igg spike - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    igg s1 quant (alinity)  (Abbott Laboratories)
    90
    Abbott Laboratories igg s1 quant (alinity)
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Igg S1 Quant (Alinity), supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/igg+s1+quant++architect+/pmc08888213__21___1885___Techapp___s1-22-220-219
    Average 90 stars, based on 1 article reviews
    igg s1 quant (alinity) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    igg s1 quant (architect)  (Abbott Laboratories)
    90
    Abbott Laboratories igg s1 quant (architect)
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Igg S1 Quant (Architect), supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/igg+s1+quant++architect+/pmc08888213__21___1885___Techapp___s1-22-260-259
    Average 90 stars, based on 1 article reviews
    igg s1 quant (architect) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    igg s1 quant  (EUROIMMUN)
    90
    EUROIMMUN igg s1 quant
    ( A ) Reciprocal titers of <t>SARS-CoV-2</t> neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.
    Igg S1 Quant, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/igg+s1+quant/anti+sars+cov+2+elisa++igg+/pmc08888213__21___1885___Techapp___s1-22-39-39
    Average 90 stars, based on 1 article reviews
    igg s1 quant - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.

    Journal: PLoS ONE

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    doi: 10.1371/journal.pone.0263861

    Figure Lengend Snippet: ( A ) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with 90% inhibition (FRNT 90 ). ( B ) RBD IgGAM signals determined as sample/cut-off ratios ( C ) S1 quant IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). ( D-E ) S1-IgA and inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios. The horizontal dotted lines represent positivity cut-offs. * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant. x-marked data points represent vaccinees with a previous SARS-CoV-2 infection.

    Article Snippet: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).

    Techniques: Neutralization, Inhibition, Binding Assay, Infection

    Ratios between SARS-CoV-2 neutralizing antibody titers and ( A, C, D ) RBD IgGAM, S1 IgA, IWV in sample/calibrator ratios and ( B ) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2–3 mild and 4–5 severe). * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Journal: PLoS ONE

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    doi: 10.1371/journal.pone.0263861

    Figure Lengend Snippet: Ratios between SARS-CoV-2 neutralizing antibody titers and ( A, C, D ) RBD IgGAM, S1 IgA, IWV in sample/calibrator ratios and ( B ) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2–3 mild and 4–5 severe). * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Article Snippet: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).

    Techniques:

    (A) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with inhibitor titer 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine sera calculated as ratio of value on timepoint P1 to timepoint P3.

    Journal: PLoS ONE

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    doi: 10.1371/journal.pone.0263861

    Figure Lengend Snippet: (A) Reciprocal titers of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with inhibitor titer 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine sera calculated as ratio of value on timepoint P1 to timepoint P3.

    Article Snippet: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).

    Techniques: Neutralization, Binding Assay

    The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Proportion of individuals with remaining nAbs in percent. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Journal: PLoS ONE

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    doi: 10.1371/journal.pone.0263861

    Figure Lengend Snippet: The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Proportion of individuals with remaining nAbs in percent. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Article Snippet: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).

    Techniques: Neutralization, Inhibition

    SARS-CoV-2 nAb titers on the wildtype strain wt-BavPat1 and the VOC strains Delta, Beta and Omicron after third vaccination (Boost) (A) compared to P1 two weeks after second vaccination and (B) compared to P3 8 months after first and third vaccination (Boost). Only individuals that had provided samples at both time points were compared. The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Mean neutralizing titer reductions are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Journal: PLoS ONE

    Article Title: Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

    doi: 10.1371/journal.pone.0263861

    Figure Lengend Snippet: SARS-CoV-2 nAb titers on the wildtype strain wt-BavPat1 and the VOC strains Delta, Beta and Omicron after third vaccination (Boost) (A) compared to P1 two weeks after second vaccination and (B) compared to P3 8 months after first and third vaccination (Boost). Only individuals that had provided samples at both time points were compared. The dotted line indicates the limit-of-detection at a titer of 1:5. FRNT90: Focus reduction neutralization titer at 90% virus inhibition; results plotted as reciprocal values. Mean neutralizing titer reductions are depicted above the continuous lines * = p <0.05, ** = p <0.01, *** = p <0.001, **** = p <0.0001, ns = not significant.

    Article Snippet: All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥0.8).

    Techniques: Neutralization, Inhibition